CRISM Therapeutics Corporation (LSE:CRTX) — Market Cap & Net Worth
Market Cap & Net Worth: CRISM Therapeutics Corporation (CRTX)
CRISM Therapeutics Corporation (LSE:CRTX) has a market capitalization of $108.39K (GBX890.83 Million) as of September 17, 2026. Listed on the LSE stock exchange, this UK-based company holds position #31480 globally and #1114 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CRISM Therapeutics Corporation's stock price GBX11.25 by its total outstanding shares 79185266 (79.19 Million). Also see CRTX current and non-current assets for a full breakdown of the balance sheet.
CRISM Therapeutics Corporation Market Cap History: 2015 to 2026
CRISM Therapeutics Corporation's market capitalization history from 2015 to 2026. Data shows change from $11.91 Million to $108.39K (-38.19% CAGR). Also see how efficiently does CRISM Therapeutics Corporation generate cash for how efficiently the company converts equity into cash flow.
CRISM Therapeutics Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CRISM Therapeutics Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check CRISM Therapeutics Corporation stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.42x
CRISM Therapeutics Corporation's market cap is 0.42 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $138.74K | $56.88K | -$247.74K | 2.44x | N/A |
| 2024 | $105.98K | $19.98K | -$485.05K | 5.31x | N/A |
| 2025 | $96.35K | $231.00K | -$1.90 Million | 0.42x | N/A |
Competitor Companies of CRTX by Market Capitalization
Companies near CRISM Therapeutics Corporation in the global market cap rankings as of September 17, 2026. Review tangible net worth ratio of CRISM Therapeutics Corporation to assess the quality of the company's equity after excluding intangible assets.
Key companies related to CRISM Therapeutics Corporation by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
CRISM Therapeutics Corporation Historical Marketcap From 2015 to 2026
Between 2015 and today, CRISM Therapeutics Corporation's market cap moved from $11.91 Million to $ 108.39K, with a yearly change of -38.19%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX108.39K | +12.50% |
| 2025 | GBX96.35K | -9.09% |
| 2024 | GBX105.98K | -23.61% |
| 2023 | GBX138.74K | -90.94% |
| 2022 | GBX1.53 Million | -41.35% |
| 2021 | GBX2.61 Million | +6.56% |
| 2020 | GBX2.45 Million | -19.40% |
| 2019 | GBX3.04 Million | -50.99% |
| 2018 | GBX6.21 Million | -43.24% |
| 2017 | GBX10.93 Million | -27.93% |
| 2016 | GBX15.17 Million | +27.33% |
| 2015 | GBX11.91 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of CRISM Therapeutics Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $108.39K USD |
| MoneyControl | $108.39K USD |
| MarketWatch | $108.39K USD |
| marketcap.company | $108.39K USD |
| Reuters | $108.39K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CRISM Therapeutics Corporation
CRISM Therapeutics Corporation develops a drug delivery technology for the clinical performance of cancer treatments for solid tumors through the local delivery of chemotherapy drugs in the British Virgin Islands. The company's lead product is ChemoSeed, which can be implanted directly into the tumour or the resection margin following the removal of a tumour. It also provides formulation and cons… Read more